Mongodb Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Mongodb Inc trades at $372.27 (market cap $29.24B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: Mongodb Inc is far larger — about 12.8× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals.
| MDB | SLS | |
|---|---|---|
Market Cap | $29.24B | $2.28B |
Volume | 1,304,995 | 3,128,960 |
Sector | Technology | Health |
52-Week High | $472.29 | $15.46 |
52-Week Low | $225.95 | $1.39 |
Typical Hold Time | 45 Days | — |
Enterprise Value | $26.86B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $371.35, up 2.95% today, showing strong momentum despite recent volatility. The stock faces bearish technical signals with resistance at $373, while fundamentals reveal impressive revenue growth from $1.7B to $2.0B in 2025, though net losses persist. Recent investor day highlighted AI product launches and raised long-term targets, but CEO transition creates uncertainty. Analyst consensus remains strongly bullish with $457 price target.
MDB presents a growth-at-a-price scenario with premium valuations (P/E 511) offset by strong revenue momentum and AI positioning. Near-term risks include leadership transition execution and competitive pressures, while the 80% buy rating suggests Wall Street sees 23% upside potential. Investors must weigh expensive multiples against transformative AI opportunities in database market.
No Aura AI signal available yet.
Trailing returns across standard periods
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →